2017
DOI: 10.12816/0046275
|View full text |Cite
|
Sign up to set email alerts
|

HLA Class II Genotyping in Chronic HCV Patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…The development of oral Direct-Acting Antivirals (DAAs), which directly block the HCV replication cycle and target three key HCV genome regions (NS3/4A protease, NS5A, and NS5B RNA-dependent polymerase) led to a significant advancement in HCV therapy [3] . Raouf et al [4] have documented the impact of numerous variables on the onset and course of disease, including genetic variants, host factors (age, sex, environment, and related medical conditions) and viral factors like viral genotype and viral load.…”
Section: Introductionmentioning
confidence: 99%
“…The development of oral Direct-Acting Antivirals (DAAs), which directly block the HCV replication cycle and target three key HCV genome regions (NS3/4A protease, NS5A, and NS5B RNA-dependent polymerase) led to a significant advancement in HCV therapy [3] . Raouf et al [4] have documented the impact of numerous variables on the onset and course of disease, including genetic variants, host factors (age, sex, environment, and related medical conditions) and viral factors like viral genotype and viral load.…”
Section: Introductionmentioning
confidence: 99%